The variety of options now accessible for the patient and physician in making appropriate and timely decisions in hereditary breast and ovarian cancer has triggered a daily increase in the demand for mutation analysis of the BRCA1/2 genes on the other continents. Here, BRCA1 is linked to ovarian carcinoma.